Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $7.73.

  • United Therapeutics' EPS (Basic) rose 1154.4% to $7.73 in Q3 2025 from the same period last year, while for Sep 2025 it was $28.48, marking a year-over-year increase of 1715.34%. This contributed to the annual value of $26.44 for FY2024, which is 2566.67% up from last year.
  • United Therapeutics' EPS (Basic) amounted to $7.73 in Q3 2025, which was up 1154.4% from $6.86 recorded in Q2 2025.
  • United Therapeutics' EPS (Basic)'s 5-year high stood at $7.73 during Q3 2025, with a 5-year trough of $0.63 in Q1 2021.
  • For the 5-year period, United Therapeutics' EPS (Basic) averaged around $5.04, with its median value being $5.31 (2022).
  • In the last 5 years, United Therapeutics' EPS (Basic) crashed by 7993.63% in 2021 and then soared by 74285.71% in 2022.
  • United Therapeutics' EPS (Basic) (Quarter) stood at $2.48 in 2021, then rose by 14.52% to $2.84 in 2022, then surged by 61.97% to $4.6 in 2023, then surged by 44.91% to $6.67 in 2024, then rose by 15.96% to $7.73 in 2025.
  • Its last three reported values are $7.73 in Q3 2025, $6.86 for Q2 2025, and $7.18 during Q1 2025.